An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + Obinutuzumab RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin's Lymphoma

Trial Profile

An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + Obinutuzumab RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin's Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GADOLIN
  • Sponsors Genentech
  • Most Recent Events

    • 27 Mar 2018 Results published in the Journal of Clinical Oncology
    • 13 May 2017 Planned End Date changed from 1 Dec 2019 to 20 Aug 2020.
    • 12 Mar 2017 Results published in the Targeted Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top